Expert Commentary on Wakefield,T.W.: The Safety,Efficacy,and Cost Efficiency of Outpatient Treatment of Acute Deep Venous Thrombosis with Low Molecular Weight Heparin (pp. 19-26)
Restricted accessOtherFirst published online December, 2000
Expert Commentary on Wakefield,T.W.: The Safety,Efficacy,and Cost Efficiency of Outpatient Treatment of Acute Deep Venous Thrombosis with Low Molecular Weight Heparin (pp. 19-26)
Dunn AS, Coller B.Outpatient treatment of deep vein thrombosis: translating clinical trials into practice. Am J Med1999;106:660-669
2.
Boccalon H., Elias A., Chalé J-J., Cadène A., Gabriel S.Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight- heparin. Arch Intern Med2000:160:1769-1773
3.
Canada T.Emerging roles of low-molecular-weight heparin derivatives in anticoagulation . http://www.InetCE.org/articles/146-000-99-003-H01.html
4.
Salartash K. , Lepore M., Gonze MD, Leone-Bay A., Baughman R., Sternbergh W., Bowen JC, Money SRTreatment of experimentally induced caval thrombosis with oral low molecular weight heparin and delivery agent in a porcine model of deep venous thrombosis. Ann Surg2000;231:789-794
5.
Gonze MD, Salartash K., Sternbergh WC, Baughman RA, Leone-Bay A., Money SROrally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation2000 ;101:2658-2661
